Terms: = Breast cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Prognosis
45 results:
1. Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to atr inhibitor treatment.
Garikapati K; Young IC; Hong S; Rai P; Jain C; Briegel KJ
Oncogene; 2024 Mar; 43(12):851-865. PubMed ID: 38297083
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of breast cancer Family History, Estrogen Receptor Status, and breast cancer Outcomes in Sweden.
Zhang Y; Wang QL; Zeng E; He W; Czene K
JAMA Netw Open; 2023 Jun; 6(6):e2318053. PubMed ID: 37310740
[TBL] [Abstract] [Full Text] [Related]
3. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.
Gampenrieder SP; Dezentjé V; Lambertini M; de Nonneville A; Marhold M; Le Du F; Cortés Salgado A; Alpuim Costa D; Vaz Batista M; Chic Ruché N; Tinchon C; Petzer A; Blondeaux E; Del Mastro L; Targato G; Bertucci F; Gonçalves A; Viret F; Bartsch R; Mannsbart C; Deleuze A; Robert L; Saavedra Serrano C; Gion Cortés M; Sampaio-Alves M; Vitorino M; Pecen L; Singer C; Harbeck N; Rinnerthaler G; Greil R;
ESMO Open; 2023 Feb; 8(1):100747. PubMed ID: 36563519
[TBL] [Abstract] [Full Text] [Related]
4. RNF126-Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple-Negative breast cancer to Radiotherapy.
Liu W; Zheng M; Zhang R; Jiang Q; Du G; Wu Y; Yang C; Li F; Li W; Wang L; Wu J; Shi L; Li W; Zhang K; Zhou Z; Liu R; Gao Y; Huang X; Fan S; Zhi X; Jiang D; Chen C
Adv Sci (Weinh); 2023 Feb; 10(5):e2203884. PubMed ID: 36563124
[TBL] [Abstract] [Full Text] [Related]
5. Rapid and low-cost liquid biopsy with atr-FTIR spectroscopy to discriminate the molecular subtypes of breast cancer.
Pereira de Souza NM; Machado BH; Padoin LV; Prá D; Fay AP; Corbellini VA; Rieger A
Talanta; 2023 Mar; 254():123858. PubMed ID: 36470017
[TBL] [Abstract] [Full Text] [Related]
6. [Is Surgery Really Useful for breast cancer Management in Elderly Patients?].
Iida Y; Fukushima W; Nakamura Y; Miyanaga S; Horikawa N; Yabushita K
Gan To Kagaku Ryoho; 2022 Sep; 49(9):957-961. PubMed ID: 36156014
[TBL] [Abstract] [Full Text] [Related]
7. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
Youn JC; Kim D; Kim KA; Kim JJ; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
Am J Transplant; 2022 Dec; 22(12):2942-2950. PubMed ID: 36050598
[TBL] [Abstract] [Full Text] [Related]
8. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
Shen K; Yao L; Zhu J; Gu X; Wang J; Qian W; Zheng Z; Fu D; Wu S
BMC Cancer; 2022 Aug; 22(1):863. PubMed ID: 35941565
[TBL] [Abstract] [Full Text] [Related]
9. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive breast cancer and Brain Metastases: ASCO Guideline Update.
Ramakrishna N; Anders CK; Lin NU; Morikawa A; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Franzoi MAB; Kirshner JJ; Krop IE; Patt DA; Perlmutter J; Giordano SH
J Clin Oncol; 2022 Aug; 40(23):2636-2655. PubMed ID: 35640075
[TBL] [Abstract] [Full Text] [Related]
10. Assessment of cell-free DNA (cfDNA) concentrations in the perioperative period can predict risk of recurrence in patients with non-metastatic breast cancer.
Hassan F; Wang JH; Cullinane C; Ita M; Corrigan M; O'Leary DP; Redmond HP
Surg Oncol; 2022 Jun; 42():101753. PubMed ID: 35594723
[TBL] [Abstract] [Full Text] [Related]
11. Secretory pathway Ca
Makena MR; Ko M; Mekile AX; Senoo N; Dang DK; Warrington J; Buckhaults P; Talbot CC; Claypool SM; Rao R
Redox Biol; 2022 Apr; 50():102240. PubMed ID: 35063802
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, cancer Antigen 153 and cancer Antigen 125 in Metastatic breast cancer.
Ma YY; Wang H; Zhao WD; Li YF; Wang JJ; Chen XY; Huang YQ; Wang WJ; Wang Y; Sun SC
Cancer Control; 2022; 29():10732748211053150. PubMed ID: 34989251
[TBL] [Abstract] [Full Text] [Related]
13. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability.
Li PP; Li RG; Huang YQ; Lu JP; Zhang WJ; Wang ZY
Aging (Albany NY); 2021 Nov; 13(21):24171-24191. PubMed ID: 34740994
[TBL] [Abstract] [Full Text] [Related]
15. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract] [Full Text] [Related]
16. [Clinical Significance of the Curative Effect after Neoadjuvant Chemotherapy for Triple-Negative breast cancer-Correlation to prognosis].
Haku E; Kojima Y; Sakamaki K; Kitajima M; Takishita M; Sakamoto N; Tazou M; Nakano M; Kuroda T; Yoshie R; Tsuruga T; Shimo A; Shimo A; Motoyoshi A; Kawamoto H; Fukuda M; Tsugawa K
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1449-1455. PubMed ID: 33130739
[TBL] [Abstract] [Full Text] [Related]
17. Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Chen H; Chong W; Yang X; Zhang Y; Sang S; Li X; Lu M
Oncoimmunology; 2020 Jun; 9(1):1788252. PubMed ID: 32923150
[TBL] [Abstract] [Full Text] [Related]
18. Angiotensin Receptor Blockers Associated with Improved breast cancer Survival-A Nationwide Cohort Study from Finland.
Santala EEE; Murto MO; Artama M; Pukkala E; Visvanathan K; Murtola TJ
Cancer Epidemiol Biomarkers Prev; 2020 Nov; 29(11):2376-2382. PubMed ID: 32917663
[TBL] [Abstract] [Full Text] [Related]
19. PIBF1 suppresses the atr/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells.
Ro EJ; Ryu SH; Park EY; Ryu JW; Byun SJ; Heo SH; Kim KH; Baek IJ; Son BH; Lee SW
Breast Cancer Res Treat; 2020 Aug; 182(3):591-600. PubMed ID: 32529408
[TBL] [Abstract] [Full Text] [Related]
20. Clinical and functional significance of tumor/stromal atr expression in breast cancer patients.
Al-Ansari MM; Al-Saif M; Arafah M; Eldali AM; Tulbah A; Al-Tweigeri T; Semlali A; Khabar KS; Aboussekhra A
Breast Cancer Res; 2020 May; 22(1):49. PubMed ID: 32414408
[TBL] [Abstract] [Full Text] [Related]
[Next]
